Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 209 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information May 17, 2022 Study Advances Fertility Preservation Approach for Male Cancer Survivors April 24, 2019 Breast Cancer Patient Credits Persistent Commercial Messaging for Saving Her Life June 9, 2020 Using a Mind-Body Connection to Help You Cope During Cancer: An... January 11, 2024 Load more HOT NEWS Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women... How to Cope with Appetite Loss in a Loved One With... NBC’s Kristen Dahlgren Discusses The Unexpected Breast Cancer Symptom She Almost... Do as I say, not as I do – when the...
